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Abstract
Introduction:  Giant prostatic adenocarcinoma represents a rare and challenging treatment
dilemma.
Case presentation: We describe a case of an otherwise healthy 71-year-old African male who
presented with a PSA of 5800 ng/ml and a prostate volume of over 1000cc. Unique aspects of this
case include the size of the prostate, the apparent absence of distant metastases, and the safe usage
of transabdominal biopsy of this mass.
Conclusion: We present this case report and review of literature to generate further discussion
amongst readers as to management options for this difficult case.
Introduction
Giant prostatic adenocarcinoma represents a rare and
challenging treatment dilemma. Previous reports [1,2]
describe a few cases of this condition and their initial clin-
ical and radiologic presentation. With increased use of
PSA screening since that time, there have been no addi-
tional cases reported in the recent literature. In this case
report, we describe an otherwise healthy male who pre-
sented with a PSA of 5800 ng/ml and a prostate volume of
over 1000cc. Unique aspects of this case include the size
of the prostate, the safe usage of transabdominal biopsy of
this mass, and the apparent absence of distant metastases.
The authors would like to generate further discussion
amongst readers as to management options for this diffi-
cult case.
Case Presentation
A 71-year-old African male was referred from an outside
hospital for further management after initially presenting
with daytime frequency and nocturia. The patient
reported symptomatic relief with tamsulosin 0.4 mg once
a day. However, a serum PSA obtained by the primary care
physician was 5874 ng/ml.
On initial presentation, he reported minimal lower uri-
nary tract symptoms. He complained of nocturia 2–3
times per night, which had improved with one month of
tamsulosin. Review of systems was negative. His past
medical history was significant for hypertension treated
with Atenolol 50 mg once a day. He had no known aller-
gies and no family history of genitourinary malignancy.
On physical exam, the patient was a well-nourished male
in no distress. Examination of his abdomen revealed a
lower abdominal suprapubic mass. Digital rectal exam
revealed a firm and markedly enlarged prostate. Labora-
tory values and urinalysis were normal. Repeat PSA was
5620 ng/ml.
A CT scan of the abdomen and pelvis demonstrated a 12
× 13 × 10 cm (1560 cm3) mass in the pelvis [Figure 1].
There was significant bilateral compression of the external
iliac vessels, and compression of the rectum. Bilateral
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mild to moderate hydroureteronephrosis was noted, and
the left kidney appeared markedly atrophic [Figure 2].
Both a nuclear medicine bone scan and plain films of the
skull were negative.
Prostate needle biopsies with 14 cores were obtained
using both a transrectal and a transabdominal approach.
All biopsy specimens demonstrated Gleason 4+4 = 8 dis-
ease in greater than 70% of the prostatic tissue except for
one biopsy, which showed Gleason grade 3+4 = 7 in less
than 15% [Figure 3].
Management
The patient was started on androgen ablation with bical-
utamide 50 mg every day for one month and a depot leu-
prolide injection two weeks after the bicalutamide was
started. He has then lost to follow up. No laboratory or
radiological studies were repeated since the initial presen-
tation.
Discussion
Three issues with this case merit discussion. First, despite
an elevated PSA of over 5800 ng/ml, this patient had no
clinical evidence of metastatic disease on either bone scan
or CT scan of the abdomen and pelvis. Others have previ-
ously reported patients with similar presentations. Stamey
et al reported three such patients, all with PSA greater than
100 ng/ml, prostate size greater than 100 gm, and cancer
arising from the transitional zone of the prostate [3]. All
three cancers were nonpalpable on DRE, and each patient
was successfully cured with surgery. It is possible that this
patient represents an extreme manifestation of this phe-
nomenon, with a massive prostate cancer and organ con-
fined disease. Or there is also the possibility that this may
be a case of giant benign prostatic hypertrophy with
underlying carcinoma. This theory is unable to be verified
without examination of the entire gross prostate speci-
men. Either way, this patient had biopsy proven cancer
that required medical intervention.
Second, the usage of ultrasound guided transabdominal
biopsy of this mass is rare, having previously only been
described by one other institution [4]. In their patient, the
suprapubic needle biopsy revealed that the mass was well
differentiated prostatic adenocarcinoma. No complica-
Transabdominal biopsy specimen showing Gleason 4+4 = 8  disease in greater than 70% of the prostatic tissue (hematox- ylin-eosin stain) Figure 3
Transabdominal biopsy specimen showing Gleason 4+4 = 8 
disease in greater than 70% of the prostatic tissue (hematox-
ylin-eosin stain).
CT scan demonstrating a 12 × 13 × 10 cm (1560 cm3) mass  in the pelvis Figure 1
CT scan demonstrating a 12 × 13 × 10 cm (1560 cm3) mass 
in the pelvis. There is significant bilateral compression of the 
external iliac vessels and rectum.
Bilateral mild to moderate hydroureteronephrosis was  noted, and the left kidney appeared markedly atrophic Figure 2
Bilateral mild to moderate hydroureteronephrosis was 
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tions were noted. In both cases, transabdominal biospy of
large pelvic masses represented a safe alternative to tran-
srectal biopsy when the transrectal approach is poorly tol-
erated. Furthermore, the advantage of the transabdominal
approach is that anterior prostate, which is not accessible
using the standard approach, can now be biopsied.
Third, this patient's treatment options appear to include
only hormonal ablation and eventual chemotherapy.
Similar cases in the literature were treated with hormonal
ablation, but all of these patients had signs of metastatic
disease at time of presentation. Recently however, Masue
et al [5] described a case giant prostate carcinoma treated
effectively with endocrine therapy. This patient, with no
evidence of metastases, could theoretically be a candidate
for neoadjuvant hormonal ablation followed by radical
prostatectomy or pelvic XRT.
Hormonal ablation has been used in men with very large
prostates to reduce the size for easier removal. This
method has shown no demonstrable benefit in 5-year
outcomes for patients undergoing radical prostatectomy
[6]. Conversely, Meyer et al found a longer disease free
survival when neoadjuvant hormonal ablation is used for
greater than 3 months prior to surgery [7]. In another
study, 4 months of neoadjuvant therapy prior to radical
prostatectomy in T3 disease found pathologic downstag-
ing to a lower stage (T2c or lower) in 48% of patients. If
responsive to androgen ablation, our patient may be a
candidate for surgery in the future.
The mechanical difficulties and risks of surgery along with
the indefinite survival benefit make the case for prostatec-
tomy difficult in our patient. If surgery is attempted, the
large size of the prostate is likely to have distorted peripro-
static anatomy, leading to poor isolation of the superficial
dorsal vein, unachievable nerve sparing, and probable
poor bladder neck preservation. Post-operatively the
patient has high risk of incontinence, impotence, and
other acute surgical morbidities. Even though surgery is
the best viable option for clinically localized prostate can-
cer, in the case of large volume adenocarcinoma the
mechanical risks may well outweigh the benefits of the
procedure.
Recently, the use of radiation and androgen ablation was
shown to have a significant benefit in men with clinically
localized prostate cancer in high-risk groups [8]. However,
no study has compared efficacy of radiation with varying
volumes of prostate. It can be inferred that the large field
size and high Gleason grades in large prostatic adenocar-
cinomas may have a low local failure rate. However, these
same variables may require higher doses of radiation and
lead to high levels of regional toxicity.
Cryotherapy is a promising alternative in our patient for
the reduction of large prostatic neoplasms. Indications for
cryoablation in our patient include localized cancer with
relative contraindications to radical prostatectomy [9].
However, cryosurgery is not currently recommended in
patients like ours with a prostate volume of >40 mL
because the large glands may prevent adequate freezing of
the prostate. Prepelica et al [10] recently found a durable
PSA biochemical disease-free survival in 83.3% of patients
and concluded that cryoablation is a feasible treatment
option in patients with organ-confined prostate carci-
noma with high-risk features (PSA ≥ 10 ng/mL, or a
Gleason sum score ≥8, or both). The study, however, did
not state the size of the treated prostate or the stage of dis-
ease, making it difficult to generalize the results for this
case. Nonetheless, in patients with large prostatic adeno-
carcinoma, cryosurgery offers patients another viable
treatment option.
Conclusion
In conclusion, giant prostatic adenocarcinoma is a rare
condition, but it poses many treatment dilemmas to the
Urologist. As with all treatment decisions, tumor class, life
expectancy, disease-free survival, treatment associated
morbidity, patient preference and physician expertise
must be taken into account.
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